Cellular Oncology

, Volume 39, Issue 3, pp 279–286 | Cite as

Tumor-specific promoter-driven adenoviral therapy for insulinoma

  • Alan Wei-Shun Tseng
  • Chiachen Chen
  • Mary B. Breslin
  • Michael S. Lan
Original Paper



Insulinomas are the most common type of neuroendocrine (NE) pancreatic islet tumors. Patients with insulinomas may develop complications associated with hyperinsulinemia. To increase the treatment options for insulinoma patients, we have tested a conditionally replicating adenovirus that has been engineered in such a way that it can specifically express therapeutic genes in NE tumors.


We used a promoter-specific adenoviral vector delivery system that is regulated by an INSM1 (insulinoma-associated-1) promoter, which is silent in normal adult tissues but active in developing NE cells and tumors. Through a series of modifications, using an insulator (HS4) and neuron-restrictive silencer elements (NRSEs), an oncolytic adenoviral vector was generated that retains tumor specificity and drives the expression of a mutated adenovirus E1A gene (Δ24E1A) and the herpes simplex virus thymidine kinase (HSV-tk) gene. The efficacy of this vector was tested in insulinoma-derived MIN, RIN, βTC-1 and pancreatic (Panc-1) cells using in vitro cell survival and in vivo tumor growth assays.


Using in vitro insulinoma-derived cell lines and an in vivo subcutaneous mouse tumor model we found that the INSM1 promoter-driven viruses were able to replicate specifically in INSM1-positive cells. INSM1-specific HSV-tk expression in combination with ganciclovir treatment resulted in dose-dependent tumor cell killing, leaving INSM1-negative cells unharmed. When we combined the INSM1-promoter driven HSV-tk with Δ24E1A and INSM1p-HSV-tk (K5) viruses, we found that the co-infected insulinoma-derived cells expressed higher levels of HSV-tk and exhibited more efficient tumor suppression than cells infected with INSM1p-HSV-tk virus alone.


INSM1 promoter-driven conditionally replicating adenoviruses may serve as a new tool for the treatment of insulinoma and may provide clinicians with additional options to combat this disease.


INSM1 Insulinoma Oncolytic Endocrine tumor Gene therapy 







neuronal restrictive silencer elements


internal ribosomal entry site


herpes simplex virus thymidine kinase




Dulbecco Modified Eagle Medium


multiplicities of infection


coxsackievirus and adenovirus receptor


  1. 1.
    C. A. Proye, Endocrine tumours of the pancreas: an update. Aust. N. Z. J. Surg. 68, 90–100 (1998)CrossRefPubMedGoogle Scholar
  2. 2.
    C. Yu, M. Wang, Z. Li, J. Xiao, F. Peng, X. Guo, Y. Deng, J. Jiang, C. Sun, MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Cell. Oncol. 38, 173–181 (2015)Google Scholar
  3. 3.
    Y. Goto, M.G. DeSilva, A. Toscani, B.S. Prabhakar, A.L. Notkins, M.S. Lan, A novel human insulinoma-associated cDNA, IA-1, encodes a protein with zinc-finger DNA-binding motifs. J. Biol. Chem. 267, 15252–15257 (1992)PubMedGoogle Scholar
  4. 4.
    M. S. Lan, M. B. Breslin, Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation. FASEB J. 23, 2024–2033 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    M. S. Gierl, N. Karoulias, H. Wende, M. Strehle, C. Birchmeier, The Zinc-finger factor Insm1 (IA-1) is essential for the development of pancreatic beta cells and intestinal endocrine cells. Genes Dev. 20, 2465–2478 (2006)CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    H. Wildner, M. S. Gierl, M. Strehle, P. Pla, C. Birchmeier, Insm1 (IA-1) is a crucial component of the transcriptional network that controls differentiation of the sympatho-adrenal lineage. Development 135, 473–481 (2008)CrossRefPubMedGoogle Scholar
  7. 7.
    H. W. Wang, M. B. Breslin, C. Chen, V. Akerstrom, Q. Zhong, M. S. Lan, INSM1-promoter driven adenoviral HSV thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors. Human Gene Ther. 20, 1308–1318 (2009)CrossRefGoogle Scholar
  8. 8.
    V. Akerstrom, C. Chen, M. S. Lan, M. B. Breslin, Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas. Cancer Gene Ther. 19, 828–838 (2012)CrossRefPubMedGoogle Scholar
  9. 9.
    F. I. Moolten, J. M. Wells, R. A. Heyman, R. M. Evans, Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Human Gene Ther. 1, 125–134 (1990)CrossRefGoogle Scholar
  10. 10.
    P. Whyte, K. J. Buchkovich, J. M. Horowitz, S. H. Friend, M. Raybuck, R. A. Weinberg, E. Harlow, Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334, 124–129 (1988)CrossRefPubMedGoogle Scholar
  11. 11.
    W. C. Ch'ng, N. Abd-Aziz, M. H. Ong, E. J. Stanbridge, N. Shafee, Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-kappaB/IkappaBalpha pathway. Cell. Oncol. 38, 279–288 (2015)Google Scholar
  12. 12.
    H. Mizuguchi, Z. Xu, A. Ishii-Watabe, E. Uchida, T. Hayakawa, IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol. Ther. 1, 376–382 (2000)CrossRefPubMedGoogle Scholar

Copyright information

© International Society for Cellular Oncology 2016

Authors and Affiliations

  • Alan Wei-Shun Tseng
    • 1
    • 2
  • Chiachen Chen
    • 1
    • 3
  • Mary B. Breslin
    • 1
    • 3
    • 4
  • Michael S. Lan
    • 1
    • 3
    • 4
    • 5
  1. 1.The Research Institute for Children, Children’s HospitalNew OrleansUSA
  2. 2.Department of Biochemistry and Molecular BiologyLouisiana State University Health Sciences CenterNew OrleansUSA
  3. 3.Laboratory of Diana Helis Henry Medical Research FoundationNew OrleansUSA
  4. 4.Department of PediatricsLouisiana State University Health Sciences CenterNew OrleansUSA
  5. 5.Department of GeneticsLouisiana State University Health Sciences CenterNew OrleansUSA

Personalised recommendations